{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-041169","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.159098+00:00","generated_at":"2026-05-16T04:07:32.516631+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO","bullets":["Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.","Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.","Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.","Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.","Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-041169","json":"https://secwatch.observer/filing/0001193125-26-041169.json","markdown":"https://secwatch.observer/filing/0001193125-26-041169.md","text":"https://secwatch.observer/filing/0001193125-26-041169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/0001193125-26-041169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/pyxs-20260206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:07:32.516631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}